Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R³⁵⁸Ala variant groups in amyotrophic lateral sclerosis patients

References

• Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10:661–70.
   PubMed Web of Science ®Google Scholar
• Harrison D, Mehta P, van Es MA, Stommel E, Drory VE, Nefussy B, et al; Pooled Resource Open-Access ALS Clinical Trials Consortium. “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:495–9.
   PubMed Web of Science ®Google Scholar
• Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve. 2019;59:10–22.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Hashizume M, Suzuki M, Mihara M. Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells. Eur J Pharmacol. 2010;634:178–83.
   PubMed Web of Science ®Google Scholar
• Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunology. 1997;158:5791–6.
   PubMed Web of Science ®Google Scholar
• Rose-John S, Neurath MF. IL-6 trans-signaling: the heat is on. Immunity. 2004;20:2–4.
   PubMed Web of Science ®Google Scholar
• Rincon M, Anguita J, Namakura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4 producing CD4+ T cells. J Exp Med. 1997;185:178–83.
   Web of Science ®Google Scholar
• Lissilaa R, Buatois V, Magistrelli G, Williams AS, Jones GW, Herren S, et al. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol. 2010;185:5512–21.
   PubMed Web of Science ®Google Scholar
• Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci. 2001;187:27–34.
   PubMed Web of Science ®Google Scholar
• Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci. 1998;154:194–9.
   PubMed Web of Science ®Google Scholar
• Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destee A, et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology. 2005;65:1958–60.
   PubMed Web of Science ®Google Scholar
• Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Lui G, et al. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegen Dis. 2012;1:305–15.
   PubMedGoogle Scholar
• Wosiski-Kuhn M, Robinson M, Strupe J, Arounleut P, Martin M, Caress J, et al. IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2019;6:e631.
   PubMed Web of Science ®Google Scholar
• Munoz-Canoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double edged sword? FEBS J. 2013;280:4131–48.
   PubMed Web of Science ®Google Scholar
• Lahiri T, Laporte JD, Moore PE, Panettieri RA, Shore SA. Interleukin-6 family cytokines: signaling and effects in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2001;280:1225–32.
   Web of Science ®Google Scholar
• Robinson MB, Deshpande DA, Chou J, Cui W, Smith S, Langefeld C, et al. IL6 trans-signaling increases expression of airway disease genes in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2015;309:129–38.
   Web of Science ®Google Scholar
• Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of interleukin-6 and tumor necrosis factor a with muscle mass and muscle strength in elderly men and women. J Gerontol A Biol Sci Med Sci. 2002;57:326–32.
   PubMed Web of Science ®Google Scholar
• Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, et al. The IL-6R alpha chain controls lung CD4 + CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest. 2005;115:313–25.
   PubMed Web of Science ®Google Scholar
• Gimeno D, Delclos GL, Ferrie JE, De Vogli R, Elovainio M, Marmot MG, et al. Association of CRP and IL-6 with lung function in a middle-aged population initially free from self-reported respiratory problems: the Whitehall II study. Eur J Epidemiol. 2011;26:135–44.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Tanaka K, Fujita T, Umezawa H, Amano H, Yoshioka K, et al. Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis. Respir Res. 2015; 6:99.
   Google Scholar
• Pronto-Laborinho A, Pinto S, Gromicho M, Pereira M, Swash M, de Carvalho M. Interleukin-6 and amyotrophic lateral sclerosis. J Neurol Sci. 2019;398:50–3.
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88.
   PubMed Web of Science ®Google Scholar
• van Dongen J, Jansen R, Smit D, Hottenga JJ, Mbarek H, Willemsen G, et al; AAGC Collaborators. The contribution of the functional IL6R polymorphism rs2228145, eQTLs and other Genome-wide SNPs to the heritability of plasma sIL-6R levels. Behav Genet. 2014;44:368–82.
   PubMed Web of Science ®Google Scholar
• Hawkins GA, Robinson MB, Hastie AT, Li X, Li H, Moore WC, et al.; National Heart, Lung, and Blood Institute–sponsored Severe Asthma Research Program (SARP). The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol. 2012;130:510–5.
   PubMed Web of Science ®Google Scholar
• Enevold C, Baslund B, Linde L, Josephsen NL, Tarp U, Lindegaard H, et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:401–5.
   PubMed Web of Science ®Google Scholar
• Campbell IL, Erta M, Lim ML, Frausto R, May U, Rose-John S, et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci. 2014;34:2503–13.
   PubMed Web of Science ®Google Scholar
• Stoica L, Keeler AM, Xiong L, Kalfopoulos M, Desrochers K, Brown Jr RH, et al. Restrictive lung disease in the Cu/Zn superoxide-dismutase 1 G93A amyotrophic lateral sclerosis mouse model. Am J Respir Cell Mol Biol. 2017;56:405–8.
   PubMed Web of Science ®Google Scholar
• Tankersley CG, Haenggeli C, Rothstein JD. Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. J Appl Physiol (1985). 2007;102:926–32.
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179–87.
   PubMed Web of Science ®Google Scholar
• Kokatnur L, Rudrappa M. Diaphragmatic palsy. Diseases 2018;6:16.
   Google Scholar
• Laroche CM, Carroll N, Moxham J, Green M. Clinical significance of severe isolated diaphragm weakness. Am Rev Respir Dis. 1988;138:862–6.
   PubMedGoogle Scholar
• Pereira MC, Mussi RFM, Massucio R. A d C, Camino AM, Barbeiro A. d S, Villalba W. d O, et al. Idiopathic bilateral diaphragmatic paresis. J Bras Pneumol. 2006;32:481–5.
   PubMedGoogle Scholar
• D'Aquino LC, Rodrigues SC, Barros JA, Rubin AS, Rosario Filho NA, Pereira CA. Predicting reduced TLC in patients with low FVC and a normal or elevated FEV1/FVC ratio. J Bras Pneumol. 2010;36:460–7.
   PubMed Web of Science ®Google Scholar
• Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J. 2004;18:992–4.
   PubMed Web of Science ®Google Scholar
• Keller P, Keller C, Carey AL, Jauffred S, Fischer CP, Steensberg A, et al. Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6. Biochem Biophys Res Commun. 2003;310:550–4.
   PubMed Web of Science ®Google Scholar
• Kosmidou I, Vassilakopoulos T, Xagorari A, Zakynthinos S, Papapetropoulos A, Roussos C. Production of interleukin-6 by skeletal myotubes: role of reactive oxygen species. Am J Respir Cell Mol Biol. 2002;26:587–93.
   PubMed Web of Science ®Google Scholar
• Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, suzuki k, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 1996;97:244–9.
   PubMed Web of Science ®Google Scholar
• van Hees HW, Schellekens WJ, Linkels M, Leenders F, Zoll J, Donders R, et al. Plasma from septic shock patients induces loss of muscle protein. Crit Care. 2011;15:R233.
   PubMed Web of Science ®Google Scholar
• Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 2007;69:113–7.
   PubMed Web of Science ®Google Scholar
• Shyh-Chang N. Metabolic Changes During Cancer Cachexia Pathogenesis. Adv Exp Med Biol. 2017;1026:233–49.
   PubMed Web of Science ®Google Scholar
• Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, et al.; WFN Research Group On ALS/MND. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291–2.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Thakore NJ, Lapin BR, Pioro EP; Pooled Resource Open-Access ALS Clinical Trials Consortium. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve. 2018;57:937–45.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003;74:1258–61.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Predictors of long survival in amyotrophic lateral sclerosis: a population-based study. J Neurol Sci. 2008;268:28–32.
   PubMed Web of Science ®Google Scholar
• Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology. 2005;25:114–9.
   PubMed Web of Science ®Google Scholar
• Suh MR, Choi WA, Choi YC, Lee JW, Hong JH, Park J, et al. Long-term outcome of amyotrophic lateral sclerosis in Korean subjects. Ann Rehabil Med. 2017;41:1055–64.
   PubMedGoogle Scholar
• Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719–25.
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al.; Eurals Consortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
   PubMed Web of Science ®Google Scholar
• Javad Mousavi SA, Zamani B, Shahabi Shahmiri S, Rohani M, Shahidi GA, Mostafapour E, et al. Pulmonary function tests in patients with amyotrophic lateral sclerosis and the association between these tests and survival. Iran J Neurol 2014;13:131–7.
   PubMedGoogle Scholar
• Wang MD, Little J, Gomes J, Cashman NR, Krewski D. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology 2017;61:101–30.
   PubMed Web of Science ®Google Scholar
• Vinsant S, Mansfield C, Jimenez-Moreno R, Del Gaizo Moore V, Yoshikawa M, Hampton TG, et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain Behav. 2013;3:431–57.
   PubMed Web of Science ®Google Scholar
• Vinsant S, Mansfield C, Jimenez-Moreno R, Del Gaizo Moore V, Yoshikawa M, Hampton TG, et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part I, background and methods. Brain Behav. 2013;3:335–50.
   PubMed Web of Science ®Google Scholar
• Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185:232–40.
   PubMed Web of Science ®Google Scholar
• Bolin LM, Verity AN, Silver JE, Shooter EM, Abrams JS. Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J Neurochem. 1995;64:850–8.
   PubMed Web of Science ®Google Scholar
• Yamada M, Hatanaka H. Interleukin-6 protects cultured rat hippocampal neurons against glutamate-induced cell death. Brain Res. 1994;643:173–80.
   PubMed Web of Science ®Google Scholar
• Bach JR. Pathophysiology of paralytic-restrictive pulmonary syndromes. In: Bach JR, editor. Pulmonary rehabilitation: the obstructive and paralytic conditions. Philadelphia, PA: Hanley & Belfus; 1996:275–83.
   Google Scholar
• Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, et al. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6J Biol Chem. 1995;270:11463–71.
   PubMed Web of Science ®Google Scholar
• Tsuchida S, Engelberts D, Peltekova V, Hopkins N, Frndova H, Babyn P, et al. Atelectasis causes alveolar injury in nonatelectatic lung regions. Am J Respir Crit Care Med. 2006;174:279–89.
   PubMed Web of Science ®Google Scholar
• De S, Souhrada M, Zelazny ET, Souhrada JF. IL-1 beta and IL-6 induce hyperplasia and hypertrophy of cultured guinea pig airway smooth muscle cells. J Appl Physiol. 1995;78:1555–63.
   PubMed Web of Science ®Google Scholar
• Jiang JH, Yang EJ, Baek MG, Kim SH, Lee SM, Choi SM. Anti-inflammatory effects of electroacupuncture in the respiratory system of a symptomatic amyotrophic lateral sclerosis animal model. Neurodegener Dis. 2011;8:504–14.
   PubMed Web of Science ®Google Scholar
• Hardiman O. Management of respiratory symptoms in ALS. J Neurol. 2011;258:359–65.
   PubMed Web of Science ®Google Scholar
• Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, et al. The natural history of amyotrophic lateral sclerosis. Neurology. 1993;43:1316–22.
   PubMed Web of Science ®Google Scholar
• Cooperstock M. Atelectasis complicating acute poliomyelitis with involvement of respiratory muscles. Arch Pediatr Adolesc Med. 1944;67:457–62.
   Google Scholar
• Schmidt-Nowara WW, Altman AR. Atelectasis and neuromuscular respiratory failure. Chest. 1984;85:792–5.
   PubMed Web of Science ®Google Scholar
• Jacobson G, Cohen SR, Carter RA. Pulmonary complications of acute bulbar poliomyelitis. Radiology. 1951;57:629–41.
   PubMed Web of Science ®Google Scholar